MONTREAL, QUEBEC--(MARKET WIRE)--Feb 18, 2008 -- Mistral Pharma Inc. (CDNX:MIP.V - News) (“Mistral”) today announced that it has signed a distribution agreement with an undisclosed pharmaceutical company for 6 injectable generic products for the Canadian market. Mistral expects to file these products with Health Canada during 2008. Mistral estimates that these products target a total market of more than $ 50 M.
“We are very excited to file these 6 additional products with Health Canada in 2008" commented Dalal Manoli, Mistral’s Vice President, Sales & Marketing. “This will strengthen our position as a specialty pharma company with a focus on hospital products” she added.
About Mistral Pharma Inc.
Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01, MIST-B02, MIST-B03 & MIST-B04, showed positive results at their respective first pilot clinical trials. Mistral also markets INSTILLAGEL® in Canada, a local anesthetic and antiseptic combination product used for urology procedures. Mistral has also in-licensed TAMALIS(TM) (Rupatadine) a new antihistamine and INSTILLAQUILL®, a single use extension tube used in gynecology. They will both be filed with Health Canada in 2008. Mistral positions itself as a development and marketing partner with pharmaceutical companies. More information is available on Mistral’s website at www.mistralpharma.com.
Forward-looking Statements
Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on Management’s best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma’s products, the impact of price pressures exerted by competitors, results from clinical studies and regulatory approval process as well as general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.
Contact:
Contacts: Mistral Pharma Inc. Bertrand F. Bolduc, B.Pharm., MBA President & Chief Executive Officer 514-421-1717 ext. 2224 bbolduc@mistralpharma.com
Mistral Pharma Inc. Alain Provencher Vice-president, Finances and Chief Financial Officer 514-421-1717 ext. 2232 aprovencher@mistralpharma.com
Source: Mistral Pharma Inc.
